Obesity News & Analysis
19 articles
Market Mood
Eli Lilly (LLY) Q3 Earnings Beat With $24.4B Revenue, Raises 2026 Sales Outlook
Eli Lilly (LLY) reported third-quarter earnings that surpassed Wall Street estimates, with adjusted earnings per share of $7.48 beating the expected $6.26. Revenue reached $24.40 billion, well above the $22.61 billion analysts predicted. The company also raised its 2026 revenue outlook to a range of $91 billion to $92 billion, up from the previous $85 billion to $87 billion forecast. The strong performance was driven by increased demand for Eli Lilly’s weight loss drug Zepbound and diabetes treatment Mounjaro. Worldwide revenue for Mounjaro rose 65% to $10.72 billion, including roughly $5 billion in U.S. sales. International sales for Mounjaro jumped 93%. Zepbound generated $5.35 billion in third-quarter revenue, a 49% increase year-over-year, mostly from U.S. sales. However, sales of the newer GLP-1 obesity pill Foundayo were below expectations. Despite pricing pressures from a U.S. drug pricing deal, Eli Lilly maintained growth and expanded full-year adjusted earnings per share guidance to between $35 and $36. Eli Lilly’s shares rose about 4% in premarket trading after the report. The company’s ongoing success with Zepbound and Mounjaro sustains its market share lead over competitor Novo Nordisk despite lower net prices. Eli Lilly is also investing in new therapeutic areas, most recently announcing a deal to acquire Merida Biosciences for autoimmune and allergic disease treatments. This strong quarterly performance and raised guidance signal sustained revenue growth for Eli Lilly, impacting expected earnings and valuation for investors.
Read More: Eli Lilly (LLY) Q3 Earnings Beat With $24.4B Revenue, Raises 2026 Sales Outlook
Weight-Loss Drug Developers Seek Market Share Amid Competition
Pharmaceutical companies are actively competing to release weight-loss drugs, tapping into a highly lucrative market. The growing prevalence of obesity has driven demand for effective weight-management solutions, prompting several companies to invest heavily in drug development. This competitive landscape includes prominent players focusing on bringing new therapies to market, each aiming to gain a portion of this booming industry. Analysts suggest that success in this market could significantly boost revenues for the companies involved, as consumer demand remains strong. Investors are closely watching developments in this sector, given the potential financial rewards of successful product launches.
Read More: Weight-Loss Drug Developers Seek Market Share Amid Competition
Viking Therapeutics (VKTX) Shares Soar on Obesity Drug Data Release
Viking Therapeutics (VKTX) has experienced a significant increase in stock price following positive data regarding its obesity drug. Meanwhile, competitors Eli Lilly and Novo Nordisk saw declines. The specifics regarding the percentage increase in Viking's stock and changes for its competitors were not provided in the article. This significant movement in shares highlights the impact of clinical data releases on stock performance in the pharmaceutical sector. Investors should note the responsiveness of biotech stocks to trial results, as successful data can lead to sharp increases in market value.
Read More: Viking Therapeutics (VKTX) Shares Soar on Obesity Drug Data Release
Eli Lilly (LLY) Sees 700,000 Seniors Start GLP-1 Treatments
Eli Lilly CEO Dave Ricks reported that since the launch of Medicare coverage for obesity drugs in July, 700,000 new seniors have begun GLP-1 treatments, with 70% opting for Lilly medications. The coverage allows eligible seniors to access weight loss drugs for a $50 monthly co-pay. Lilly's Zepbound and Foundayo are noted as leading choices among patients, with one-third of new oral GLP-1 patients using Foundayo. The increase in patients shows significant market expansion for obesity treatments, which potentially benefits Eli Lilly (LLY) significantly.
Read More: Eli Lilly (LLY) Sees 700,000 Seniors Start GLP-1 Treatments
Novo (NVO) rebrands to regain market share in obesity drugs
Novo Nordisk announced it is rebranding to 'Novo' to improve its market position in the obesity drug sector. Currently, Novo holds a 38.8% market share compared to Eli Lilly's 60.9% as of Q2, according to data cited in a Lilly earnings presentation. The company dropped about 15% in shares this year, despite over 3 million prescriptions for the oral version of Wegovy launched in June. The rebranding includes a cultural shift and new marketing initiatives aimed at building public trust and relevance, which may impact investor perception and stock performance of Novo (NVO).
Read More: Novo (NVO) rebrands to regain market share in obesity drugs
Novo Nordisk (NVO) Stock Declines Despite Increased Sales Forecast
Novo Nordisk (NVO) raised its full-year guidance, now expecting adjusted sales and operating profit to be down 6% to flat at constant exchange rates, an improvement from a previous decline expectation of 4% to 12%. Despite a quarterly earnings beat, shares fell 3.4% during the trading session and 6% in after-hours trading. Analysts highlighted that the positive results were driven by temporary factors and expressed concerns over competition from Eli Lilly. The outlook is crucial for investors as Novo attempts to regain confidence in its long-term growth amidst strong competitor pressure.
Read More: Novo Nordisk (NVO) Stock Declines Despite Increased Sales Forecast
Lilly (LLY) Obesity Drugs Approach Major Milestone in Trials
Lilly's (LLY) obesity drug candidates are nearing significant milestones in clinical trials, which could have considerable market implications. Investors are particularly focused on the upcoming data release expected to influence the company's stock performance. The expected efficacy of these drugs could lead to a substantial increase in market share within the obesity treatment sector. As obesity rates rise globally, pharmaceuticals like those from Lilly are poised for rapid growth in demand.
Read More: Lilly (LLY) Obesity Drugs Approach Major Milestone in Trials
GLP-1 Drugs: New Weight-Loss Therapies Under Development
New experimental weight-loss therapies are being developed to potentially outperform existing GLP-1 medications, such as Zepbound and Wegovy. Specific data points and timelines for these therapies are not provided in the article. The advancement in this sector could impact the market by affecting the sales and adoption of current GLP-1 products. Stakeholders in companies involved in diabetes and obesity treatments should monitor the progress of these new drug candidates.
Read More: GLP-1 Drugs: New Weight-Loss Therapies Under Development
Eli Lilly (LLY) next-gen obesity drug achieves 28.3% weight loss
Eli Lilly (LLY) announced that its next-generation obesity drug, retatrutide, successfully completed a late-stage trial, showing a significant weight loss of 28.3% on average over 80 weeks. Approximately 45% of 2,500 trial participants achieved 30% or more weight loss, and around 65% reached a BMI below 30. Analysts had anticipated retatrutide to outperform Lilly's current weight loss drug, Zepbound, which achieves about 20% to 22% weight loss. The expected sales for retatrutide could reach $3.8 billion by 2030, highlighting its potential impact in the growing weight loss and diabetes market, projected to value around $100 billion by that time.
Read More: Eli Lilly (LLY) next-gen obesity drug achieves 28.3% weight loss
Novo Nordisk (NVO) high-dose Wegovy shows 27.7% weight loss
Novo Nordisk (NVO) announced that patients taking the high-dose 7.2-milligram version of Wegovy lost an average of 27.7% of their weight over 72 weeks in a recent trial. This data was presented at the European Congress on Obesity and could assist Novo in enhancing its competitive position against Eli Lilly's (LLY) Zepbound, which has shown weight loss of over 20%. The previous highest dose of Wegovy (2.4 mg) resulted in a 17% average weight loss. Approximately 25% of patients in the higher dose trial experienced early treatment response, achieving significant weight loss early in the treatment cycle.
Read More: Novo Nordisk (NVO) high-dose Wegovy shows 27.7% weight loss
Novo Nordisk (NVO) Stock Rises 6% After Strong Wegovy Sales Data
Novo Nordisk (NVO) raised its full-year 2026 profit guidance following better-than-expected sales of its Wegovy weight-loss pill, which reached 2.26 billion kroner in Q1, above estimates of 1.16 billion kroner. The company's shares increased by 6.3% in morning trading, following prior gains over 8%. Adjusted sales and profits are expected to decline between 4% and 12% on a currency-adjusted basis, improving from prior projections. First-quarter sales were reported at 96.8 billion kroner ($15.2 billion), with operating profit surging 65% to 59.6 billion kroner.
Read More: Novo Nordisk (NVO) Stock Rises 6% After Strong Wegovy Sales Data
Eli Lilly (LLY) Reports Q1 Earnings, Raises 2026 Revenue Outlook by $2B
Eli Lilly (LLY) reported Q1 earnings of $8.55 per share and revenue of $19.80 billion, surpassing estimates of $6.66 and $17.62 billion, respectively. The company raised its 2026 revenue guidance to $82-$85 billion from $80-$83 billion. Mounjaro's revenue increased 125% to $8.66 billion, while Zepbound generated $4.16 billion in U.S. sales, an 80% year-over-year rise. With a strong 60.1% share of the U.S. obesity market, the robust demand for its products underscores Lilly's market position despite price pressures.
Read More: Eli Lilly (LLY) Reports Q1 Earnings, Raises 2026 Revenue Outlook by $2B
Lilly (LLY) obesity pill reduces cardiovascular risks in trial
Eli Lilly (LLY) announced that its Foundayo obesity pill met its trial goals by reducing the risk of major cardiovascular events by 16% in over 2,700 adults with type 2 diabetes. Compared to insulin glargine, patients taking Foundayo experienced a 57% lower risk of death from any cause. Additionally, those on Foundayo had greater reductions in blood sugar and weight, unlike patients on insulin glargine who gained weight. Eli Lilly plans to seek U.S. approval for Foundayo for type 2 diabetes by the end of Q2.
Read More: Lilly (LLY) obesity pill reduces cardiovascular risks in trial
Novo Nordisk (NVO) Wegovy Pill Launch Hits 600K Prescriptions
Novo Nordisk's (NVO) Wegovy pill, launched in early January, has seen over 600,000 prescriptions written within three months, including more than 3,000 in its first week. This surge reflects a growing demand for GLP-1 treatments as patients previously deterred by injection methods now gravitate towards the oral option. The pill is priced between $149 to $299 per month, which analysts attribute to its early success. Despite this positive start, Novo's stock price remains under pressure as competition from Eli Lilly's newly approved GLP-1 product, Foundayo, arises.
Read More: Novo Nordisk (NVO) Wegovy Pill Launch Hits 600K Prescriptions
Eli Lilly (LLY) Obesity Pill Foundayo Receives FDA Approval
Eli Lilly's (LLY) GLP-1 obesity pill, Foundayo, has received approval from the U.S. FDA. This approval is significant as it paves the way for Eli Lilly to enter the competitive weight loss drug market, where it will face off against rival Novo Nordisk. The successful approval could impact market dynamics and influence trading volumes for both companies. The development is expected to drive Eli Lilly's growth in the pharmaceutical sector and could potentially affect pricing strategies for obesity treatments.
Read More: Eli Lilly (LLY) Obesity Pill Foundayo Receives FDA Approval
Eli Lilly (LLY) wins US approval for Foundayo weight-loss drug
Eli Lilly (LLY) received US approval for its weight-loss drug, Foundayo. This approval introduces competition in the oral obesity drug market, particularly against Novo Nordisk. The specifics of the approval, including safety and efficacy data, have not been disclosed in this article. The entry of Foundayo may influence market dynamics as both companies vie for market share in the oral obesity treatment space.
Read More: Eli Lilly (LLY) wins US approval for Foundayo weight-loss drug
Eli Lilly (LLY) Receives FDA Approval for Obesity Pill
Eli Lilly (LLY) has received FDA approval for its obesity treatment pill, a significant milestone for the company. This approval may impact Eli Lilly's market position and sales potential in the competitive obesity treatment sector. FDA approvals are critical for pharmaceutical companies as they can lead to increased revenue growth. The approval could bolster investor confidence and influence stock performance in coming sessions.
Read More: Eli Lilly (LLY) Receives FDA Approval for Obesity Pill
Lilly (LLY) Wins FDA Approval for Oral Obesity Drug Foundayo
Lilly (LLY) has received FDA approval for its oral obesity drug, Foundayo. This approval may provide Lilly a competitive edge in the obesity treatment market, which has seen increasing demand. The financial impact of this approval could potentially enhance Lilly's revenue from obesity-related therapies. The wider implications for market dynamics in pharmaceutical and healthcare sectors will depend on the drug's acceptance and sales performance.
Read More: Lilly (LLY) Wins FDA Approval for Oral Obesity Drug Foundayo
Reevaluating Obesity: GLP-1s Spark Debate Over BMI's Accuracy
Recent discussions around obesity have highlighted the shortcomings of the Body Mass Index (BMI) as an indicator of health, particularly as millions now turn to GLP-1 medications for weight management. This shift raises questions about how obesity is defined and measured, which could have broader implications for healthcare policy and market dynamics in the pharmaceutical sector. With the growing prevalence of GLP-1 use, companies developing these treatments may see increased demand, impacting stock valuations and healthcare expenditures. Investors should monitor the potential shifts in health metrics and treatment approaches that could influence market strategies.
Read More: Reevaluating Obesity: GLP-1s Spark Debate Over BMI's Accuracy